Cingulate (NASDAQ:CING) Stock Breaks Above Fifty Day Moving Average – Time to Sell?

Cingulate Inc. (NASDAQ:CING)’s share price crossed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $5.02 and traded as high as $5.27. Cingulate shares last traded at $5.18, with a volume of 229,764 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Weiss Ratings raised shares of Cingulate from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 20th. Roth Capital set a $9.00 price objective on shares of Cingulate and gave the company a “buy” rating in a report on Sunday, August 23rd. Finally, Wall Street Zen raised shares of Cingulate from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.00.

Cingulate Stock Up 4.0%

The company has a 50-day moving average of $5.02 and a 200-day moving average of $5.43. The company has a market cap of $75.32 million, a PE ratio of -1.44 and a beta of -0.88.

Cingulate (NASDAQ:CING) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.18. As a group, equities analysts predict that Cingulate Inc. will post -2.19 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Kestra Advisory Services LLC increased its stake in Cingulate by 14.8% in the 1st quarter. Kestra Advisory Services LLC now owns 140,000 shares of the company’s stock valued at $869,000 after buying an additional 18,000 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Cingulate during the second quarter valued at approximately $291,000. Renaissance Technologies LLC purchased a new stake in shares of Cingulate during the first quarter valued at approximately $198,000. Finally, Chicago Partners Investment Group LLC purchased a new stake in shares of Cingulate during the first quarter valued at approximately $116,000. 41.31% of the stock is owned by institutional investors.

About Cingulate

Cingulate Inc (NASDAQ:CING) is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company’s lead programs are based on its proprietary Precision Timed Release (PTR) drug-delivery platform, which is designed to provide controlled, timed releases of medication from a single oral dose.

Cingulate’s primary product candidate is CTx-1301, an extended-release formulation of dexmethylphenidate intended to provide all-day ADHD symptom control through multiple releases of the active ingredient.